Immune Reconstitution Therapy or Continuous Immunosuppression for the Management of Active Relapsing–Remitting Multiple Sclerosis Patients? A Narrative Review

The majority of disease-modifying drugs (DMDs) available for the management of active relapsing–remitting multiple sclerosis (RMS) depend on continuous drug intake for maintained efficacy, with escalation to a more active drug when an unacceptable level of disease activity returns. Among continuousl...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neurol Ther
Autors principals: AlSharoqi, Isa Ahmed, Aljumah, Mohamed, Bohlega, Saeed, Boz, Cavit, Daif, Abdelkader, El-Koussa, Salam, Inshasi, Jihad, Kurtuncu, Murat, Müller, Thomas, Retief, Chris, Sahraian, Mohammad Ali, Shaygannejad, Vahid, Slassi, Ilham, Taha, Karim, Zakaria, Magd, Sørensen, Per Soelberg
Format: Artigo
Idioma:Inglês
Publicat: Springer Healthcare 2020
Matèries:
Review
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7229056/
https://ncbi.nlm.nih.gov/pubmed/32297127
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40120-020-00187-3
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars